{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:45Z","timestamp":1790286945354,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s13555-024-01198-w","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T07:02:27Z","timestamp":1719039747000},"page":"1755-1766","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Psoriasis in the Era of Targeted Cancer Therapeutics: A Systematic Review on De Novo and Pre-existing Psoriasis in Oncologic Patients Treated with Emerging Anti-neoplastic Agents"],"prefix":"10.1007","volume":"14","author":[{"given":"Vrinda","family":"Madan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura I.","family":"Ortiz-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goranit","family":"Sakunchotpanit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krithika","family":"Nayudu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod E.","family":"Nambudiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,22]]},"reference":[{"key":"1198_CR1","first-page":"ed16","volume":"6","author":"S Chakraborty","year":"2012","unstructured":"Chakraborty S, Rahman T. The difficulties in cancer treatment. Ecancermedicalscience. 2012;6:ed16.","journal-title":"Ecancermedicalscience"},{"issue":"23","key":"1198_CR2","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"R Bayat Mokhtari","year":"2017","unstructured":"Bayat Mokhtari R, Homayouni TS, Baluch N, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022\u201343.","journal-title":"Oncotarget"},{"key":"1198_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/B0-12-370879-6\/00351-3","volume-title":"Encyclopedia of respiratory medicine","author":"M Torres","year":"2006","unstructured":"Torres M, Forman HJ. Signal transduction. In: Laurent GJ, Shapiro SD, editors. Encyclopedia of respiratory medicine. Oxford: Academic Press; 2006. p. 10\u20138."},{"issue":"1","key":"1198_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi A, Mohammed RN, Raji A, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022;20(1):44.","journal-title":"Cell Commun Signal"},{"issue":"4","key":"1198_CR5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3322\/caac.21184","volume":"63","author":"GK Dy","year":"2013","unstructured":"Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin. 2013;63(4):249\u201379.","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 1","key":"1198_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","volume":"19","author":"M Lacouture","year":"2018","unstructured":"Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19(Suppl 1):31\u20139.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1198_CR7","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1210\/jc.2011-2677","volume":"97","author":"AC Rosen","year":"2012","unstructured":"Rosen AC, Wu S, Damse A, Sherman E, Lacouture ME. Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97(4):1125\u201333.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1198_CR8","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3892\/or.2020.7911","volume":"45","author":"EL Coleman","year":"2021","unstructured":"Coleman EL, Olamiju B, Leventhal JS. Potentially life threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (review). Oncol Rep. 2021;45(3):891\u20138.","journal-title":"Oncol Rep"},{"key":"1198_CR9","doi-asserted-by":"publisher","first-page":"1071983","DOI":"10.3389\/fimmu.2023.1071983","volume":"14","author":"T Watanabe","year":"2023","unstructured":"Watanabe T, Yamaguchi Y. Cutaneous manifestations associated with immune checkpoint inhibitors. Front Immunol. 2023;14:1071983.","journal-title":"Front Immunol"},{"issue":"5","key":"1198_CR10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMra0804595","volume":"361","author":"FO Nestle","year":"2009","unstructured":"Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496\u2013509.","journal-title":"N Engl J Med"},{"key":"1198_CR11","first-page":"73","volume":"12","author":"LI Ortiz-Lopez","year":"2022","unstructured":"Ortiz-Lopez LI, Choudhary V, Bollag WB. Updated perspectives on keratinocytes and psoriasis: keratinocytes are more than innocent byst anders. Psoriasis (Auckl). 2022;12:73\u201387.","journal-title":"Psoriasis (Auckl)"},{"issue":"2","key":"1198_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jaad.2006.09.005","volume":"56","author":"JC Hu","year":"2007","unstructured":"Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007;56(2):317\u201326.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1198_CR13","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.3390\/ijms18112420","volume":"18","author":"T Yamaoka","year":"2017","unstructured":"Yamaoka T, Ohba M, Ohmori T. Molecular-targeted therapies for epidermal growth factor receptor and its resistance mechanisms. Int J Mol Sci. 2017;18(11):2420.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1198_CR14","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1084\/jem.167.2.670","volume":"167","author":"AB Gottlieb","year":"1988","unstructured":"Gottlieb AB, Chang CK, Posnett DN, Fanelli B, Tam JP. Detection of transforming growth factor alpha in normal, malignant, and hyperproliferative human keratinocytes. J Exp Med. 1988;167(2):670\u20135.","journal-title":"J Exp Med"},{"issue":"4892","key":"1198_CR15","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1126\/science.2916128","volume":"243","author":"JT Elder","year":"1989","unstructured":"Elder JT, Fisher GJ, Lindquist PB, et al. Overexpression of transforming growth factor alpha in psoriatic epidermis. Science. 1989;243(4892):811\u20134.","journal-title":"Science"},{"issue":"3","key":"1198_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00403-003-0391-x","volume":"295","author":"M Piepkorn","year":"2003","unstructured":"Piepkorn M, Predd H, Underwood R, Cook P. Proliferation-differentiation relationships in the expression of heparin-binding epidermal growth factor-related factors and ErbB receptors by normal and psoriatic human keratinocytes. Arch Dermatol Res. 2003;295(3):93\u2013101.","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"1198_CR17","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1002\/eji.202149706","volume":"52","author":"X Dai","year":"2022","unstructured":"Dai X, Murakami M, Shiraishi K, et al. EGFR ligands synergistically increase IL-17A-induced expression of psoriasis signature genes in human keratinocytes via I\u03baB\u03b6 and Bcl3. Eur J Immunol. 2022;52(6):994\u20131005.","journal-title":"Eur J Immunol"},{"issue":"1","key":"1198_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1365-2133.2004.06304.x","volume":"152","author":"C Johansen","year":"2005","unstructured":"Johansen C, Kragballe K, Westergaard M, Henningsen J, Kristiansen K, Iversen L. The mitogen-activated protein kinases p38 and ERK1\/2 are increased in lesional psoriatic skin. Br J Dermatol. 2005;152(1):37\u201342.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1198_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaad.2011.08.009","volume":"66","author":"N Oyama","year":"2012","unstructured":"Oyama N, Kaneko F, Togashi A, Yamamoto T. A case of rapid improvement of severe psoriasis during molecular-targeted therapy using an epidermal growth factor receptor tyrosine kinase inhibitor for metastatic lung adenocarcinoma. J Am Acad Dermatol. 2012;66(6):251.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1198_CR20","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1111\/jdv.14862","volume":"32","author":"L Goepel","year":"2018","unstructured":"Goepel L, Jacobi A, Augustin M, Radtke MA. Rapid improvement of psoriasis in a patient with lung cancer after treatment with erlotinib. J Eur Acad Dermatol Venereol. 2018;32(8):e311\u20133.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1198_CR21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1684\/ejd.2010.0882","volume":"20","author":"E Giroux Leprieur","year":"2010","unstructured":"Giroux Leprieur E, Friard S, Couderc L. Improvement of psoriasis in a lung cancer patient treated with erlotinib. Eur J Dermatol. 2010;20(2):243\u20134.","journal-title":"Eur J Dermatol"},{"issue":"2","key":"1198_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1159\/000342786","volume":"225","author":"TR Overbeck","year":"2012","unstructured":"Overbeck TR, Griesinger F. Two cases of psoriasis responding to erlotinib: time to revisiting inhibition of epidermal growth factor receptor in psoriasis therapy? Dermatology. 2012;225(2):179\u201382.","journal-title":"Dermatology"},{"issue":"12","key":"1198_CR23","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.3748\/wjg.v21.i12.3746","volume":"21","author":"K Okamoto","year":"2015","unstructured":"Okamoto K, Maeda H, Shiga T, et al. Cetuximab and panitumumab in a patient with colon cancer and concomitant chronic skin disease: a potential beneficial effect on psoriasis vulgaris. World J Gastroenterol. 2015;21(12):3746\u20139.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"1198_CR24","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1080\/02841860410020211","volume":"43","author":"F Trivin","year":"2004","unstructured":"Trivin F, Boucher E, Raoul J. Complete sustained regression of extensive psoriasis with cetuximab combination chemotherapy. Acta Oncol. 2004;43(6):592\u20133.","journal-title":"Acta Oncol"},{"issue":"4","key":"1198_CR25","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3747\/co.v15i4.228","volume":"15","author":"B Neyns","year":"2008","unstructured":"Neyns B, Meert V, Vandenbroucke F. Cetuximab treatment in a patient with metastatic colorectal cancer and psoriasis. Curr Oncol. 2008;15(4):196\u20137.","journal-title":"Curr Oncol"},{"issue":"2","key":"1198_CR26","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/ajd.13203","volume":"61","author":"K Shiraishi","year":"2020","unstructured":"Shiraishi K, Akiyama S, Tohyama M, Sayama K. Improvement of psoriasis in a patient with metastatic colon cancer after treatment with panitumumab. Australas J Dermatol. 2020;61(2):171\u20133.","journal-title":"Australas J Dermatol"},{"issue":"4","key":"1198_CR27","doi-asserted-by":"publisher","first-page":"360","DOI":"10.2340\/00015555-1348","volume":"92","author":"A Nishizawa","year":"2012","unstructured":"Nishizawa A, Satoh T, Yokozeki H. Erythrodermic psoriasis improved by panitumumab, but not bevacizumab. Acta Derm Venereol. 2012;92(4):360\u20131.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"1198_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1634\/theoncologist.2012-0219","volume":"18","author":"MB Brooks","year":"2013","unstructured":"Brooks MB. Erlotinib and gefitinib, epidermal growth factor receptor kinase inhibitors, may treat non-cancer-related tumor necrosis factor-\u03b1 mediated inflammatory diseases. Oncologist. 2013;18(1):3.","journal-title":"Oncologist"},{"issue":"1","key":"1198_CR29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1440-0960.2010.00675.x","volume":"52","author":"A Mas-Vidal","year":"2011","unstructured":"Mas-Vidal A, Coto-Segura P, Galache-Osuna C, Santos-Juanes J. Psoriasis induced by cetuximab: a paradoxical adverse effect. Australas J Dermatol. 2011;52(1):56\u20138.","journal-title":"Australas J Dermatol"},{"key":"1198_CR30","doi-asserted-by":"publisher","first-page":"bcr2016214582","DOI":"10.1136\/bcr-2016-214582","volume":"2016","author":"E Marinello","year":"2016","unstructured":"Marinello E, Pastorelli D, Alaibac M. A case of psoriasis pustolosa palmaris induced by cetuximab. BMJ Case Rep. 2016;2016:bcr2016214582.","journal-title":"BMJ Case Rep"},{"issue":"4","key":"1198_CR31","volume":"14","author":"R Rittberg","year":"2022","unstructured":"Rittberg R, Ho C, Wang Y. Acute onset of a life-threatening skin toxicity due to osimertinib: severe psoriasis versus toxic epidermal necrolysis. Cureus. 2022;14(4): e24513.","journal-title":"Cureus."},{"issue":"2","key":"1198_CR32","doi-asserted-by":"publisher","first-page":"216","DOI":"10.4274\/Tjh.2012.0147","volume":"30","author":"F Atalay","year":"2013","unstructured":"Atalay F, K\u0131z\u0131lk\u0131l\u0131\u00e7 E, Ada RS. Imatinib-induced psoriasis. Turk J Haematol. 2013;30(2):216\u20138.","journal-title":"Turk J Haematol"},{"key":"1198_CR33","doi-asserted-by":"crossref","unstructured":"Cheng H, Geist DE, Piperdi M, Virk R, Piper B. Management of imatinib-related exacerbation of psoriasis in a patient with a gastrointestinal stromal tumour. Australas J Dermatol. 2009;50(1):41-3.","DOI":"10.1111\/j.1440-0960.2008.00495.x"},{"key":"1198_CR34","doi-asserted-by":"crossref","unstructured":"Dickens E, Lewis F, Bienz N. Imatinib: a designer drug, another cutaneous complication. Clin Exp Dermatol. 2009;34(5):603-4","DOI":"10.1111\/j.1365-2230.2009.03250.x"},{"issue":"1","key":"1198_CR35","first-page":"26","volume":"34","author":"H Lin","year":"2016","unstructured":"Lin H, Hsu C, Cheng S, Chang C. Imatinib-induced exacerbation of psoriasis in a patient with recurrent dermatofibrosarcoma protuberans: a case report and review of the literature. Zh\u014dnghu\u00e1 P\u00edf\u016bk\u0113 Y\u012bxu\u00e9 Z\u00e1zh\u00ec. 2016;34(1):26\u20138.","journal-title":"Zh\u014dnghu\u00e1 P\u00edf\u016bk\u0113 Y\u012bxu\u00e9 Z\u00e1zh\u00ec"},{"issue":"10","key":"1198_CR36","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/j.1346-8138.2007.00369.x","volume":"34","author":"SM Woo","year":"2007","unstructured":"Woo SM, Huh CH, Park KC, Youn SW. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib. J Dermatol. 2007;34(10):724\u20136.","journal-title":"J Dermatol"},{"key":"1198_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2022.100676","volume":"96","author":"SF Sadatmadani","year":"2022","unstructured":"Sadatmadani SF, Malakoutikhah Z, Mohaghegh F, Peikar M, Saboktakin M. Nilotinib-induced elephantine psoriasis in a patient with chronic myeloid leukemia: a rare case report and literature review. Curr Ther Res Clin Exp. 2022;96:100676.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"2","key":"1198_CR38","doi-asserted-by":"publisher","first-page":"216","DOI":"10.4103\/0378-6323.152311","volume":"81","author":"S Kaur","year":"2015","unstructured":"Kaur S, Arora AK, Sekhon JS, Sood N. Nilotinib-induced psoriasis in a patient of chronic myeloid leukemia responding to methotrexate. Indian J Dermatol Venereol Leprol. 2015;81(2):216\u20138.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"3","key":"1198_CR39","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/ejh.12153","volume":"91","author":"T Nagai","year":"2013","unstructured":"Nagai T, Karakawa M, Komine M, Muroi K, Ohtsuki M, Ozawa K. Development of psoriasis in a patient with chronic myelogenous leukaemia during nilotinib treatment. Eur J Haematol. 2013;91(3):270\u20132.","journal-title":"Eur J Haematol"},{"key":"1198_CR40","doi-asserted-by":"crossref","unstructured":"Thekkudan SF, Nityanand S. Development of psoriasis vulgaris in a chronic myeloid leukemia patient on second-generation tyrosine kinase inhibitor therapy. J Leuk. 2017;05:229.","DOI":"10.4172\/2329-6917.1000229"},{"issue":"1","key":"1198_CR41","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s12288-019-01162-1","volume":"36","author":"A Jain","year":"2020","unstructured":"Jain A. Imatinib induced complete remission of psoriasis in a patient with chronic myeloid leukemia. Indian J Hematol Blood Transfus. 2020;36(1):198\u20139.","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"2","key":"1198_CR42","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1046\/j.1365-2133.2002.497217.x","volume":"147","author":"S Miyagawa","year":"2002","unstructured":"Miyagawa S, Fujimoto H, Ko S, Hirota S, Kitamura Y. Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour. Br J Dermatol. 2002;147(2):406\u20137.","journal-title":"Br J Dermatol"},{"issue":"17","key":"1198_CR43","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.3390\/jcm10173880","volume":"10","author":"N Kanda","year":"2021","unstructured":"Kanda N, Hoashi T, Saeki H. The defect in regulatory T Cells in psoriasis and therapeutic approaches. J Clin Med. 2021;10(17):3880.","journal-title":"J Clin Med"},{"issue":"1","key":"1198_CR44","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/bjd.19380","volume":"184","author":"L Nussbaum","year":"2021","unstructured":"Nussbaum L, Chen YL, Ogg GS. Role of regulatory T cells in psoriasis pathogenesis and treatment. Br J Dermatol. 2021;184(1):14\u201324.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1198_CR45","first-page":"1133","volume":"31","author":"J Chen","year":"2007","unstructured":"Chen J, Schmitt A, Giannopoulos K, et al. Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner. Int J Oncol. 2007;31(5):1133\u20139.","journal-title":"Int J Oncol"},{"issue":"5b","key":"1198_CR46","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1111\/j.1582-4934.2008.00234.x","volume":"12","author":"J Chen","year":"2008","unstructured":"Chen J, Schmitt A, Chen B, et al. Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling. J Cell Mol Med. 2008;12(5b):2107\u201318.","journal-title":"J Cell Mol Med"},{"issue":"6","key":"1198_CR47","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","volume":"105","author":"R Seggewiss","year":"2005","unstructured":"Seggewiss R, Lor\u00e9 K, Greiner E, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood. 2005;105(6):2473\u20139.","journal-title":"Blood"},{"issue":"8","key":"1198_CR48","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03696.x","volume":"34","author":"J Thachil","year":"2009","unstructured":"Thachil J. T-regulatory cell response in psoriasis and changes with imatinib therapy. Clin Exp Dermatol. 2009;34(8): e1022.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"1198_CR49","first-page":"677","volume":"30","author":"EA Antoniou","year":"2016","unstructured":"Antoniou EA, Koutsounas I, Damaskos C, Koutsounas S. Remission of psoriasis in a patient with hepatocellular carcinoma treated with sorafenib. In Vivo. 2016;30(5):677\u201380.","journal-title":"In Vivo"},{"issue":"3","key":"1198_CR50","first-page":"E11","volume":"104","author":"CJ Ensslin","year":"2019","unstructured":"Ensslin CJ, Kao P, Wu M, et al. Psoriasiform drug eruption secondary to sorafenib: case series and review of the literature. Cutis. 2019;104(3):E11\u20135.","journal-title":"Cutis"},{"issue":"5","key":"1198_CR51","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1365-2230.2008.02991.x","volume":"34","author":"A Akman","year":"2009","unstructured":"Akman A, Yilmaz E, Mutlu H, Ozdogan M. Complete remission of psoriasis following 426 bevacizumab therapy for colon cancer. Clin Exp Dermatol. 2009;34(5):202.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"1198_CR52","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/MAJ.0b013e3181dd1aa5","volume":"339","author":"S Narayanan","year":"2010","unstructured":"Narayanan S, Callis-Duffin K, Batten J, Agarwal N. Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. Am J Med Sci. 2010;339(6):580\u20131.","journal-title":"Am J Med Sci"},{"issue":"12","key":"1198_CR53","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/1346-8138.12289","volume":"40","author":"Y Kato","year":"2013","unstructured":"Kato Y, Yamamoto T. Dramatic effect of sunitinib with rapid but transient improvement for psoriasis in a patient with metastatic renal carcinoma. J Dermatol. 2013;40(12):1069\u201370.","journal-title":"J Dermatol"},{"issue":"11","key":"1198_CR54","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1093\/rheumatology\/kew281","volume":"55","author":"S Law-Ping-Man","year":"2016","unstructured":"Law-Ping-Man S, Martin A, Briens E, Tisseau L, Safa G. Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer. Rheumatology (Oxford). 2016;55(11):2087\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1198_CR55","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L. PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727\u201342.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"1198_CR56","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/15569527.2022.2034842","volume":"41","author":"M Bhardwaj","year":"2022","unstructured":"Bhardwaj M, Chiu MN, Pilkhwal SS. Adverse cutaneous toxicities by PD-1\/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance. Cutan Ocul Toxicol. 2022;41(1):73\u201390.","journal-title":"Cutan Ocul Toxicol"},{"issue":"1","key":"1198_CR57","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1177\/1078155219877234","volume":"26","author":"CD Guven","year":"2020","unstructured":"Guven CD, Kilickap S, Guner G, Taban H, Dizdar O. Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer. J Oncol Pharm Pract. 2020;26(1):256\u20138.","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"1198_CR58","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1001\/jamadermatol.2015.5210","volume":"152","author":"MB Totonchy","year":"2016","unstructured":"Totonchy MB, Ezaldein HH, Ko CJ, Choi JN. Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma. JAMA Dermatol. 2016;152(5):590\u20132.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1198_CR59","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14830","volume":"34","author":"P Cutroneo","year":"2021","unstructured":"Cutroneo P, Ingrasciotta Y, Isgr\u00f2 V, et al. Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors. Dermatol Ther. 2021;34(2): e14830.","journal-title":"Dermatol Ther"},{"issue":"5","key":"1198_CR60","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.jaad.2020.08.137","volume":"84","author":"V Nikolaou","year":"2021","unstructured":"Nikolaou V, Sibaud V, Fattore D, et al. Immune checkpoint-mediated psoriasis: a multicenter European study of 115 patients from the European network for cutaneous adverse event to oncologic drugs (ENCADO) group. J Am Acad Dermatol. 2021;84(5):1310\u201320.","journal-title":"J Am Acad Dermatol"},{"key":"1198_CR61","doi-asserted-by":"crossref","unstructured":"Tarafdar N, Sachdeva M, Savinova I, et al. Onset of psoriasis with immune checkpoint inhibitor therapy: a systematic review. J Am Acad Dermatol. 2024;90(2):392-395.","DOI":"10.1016\/j.jaad.2023.09.070"},{"issue":"2","key":"1198_CR62","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jaad.2022.02.030","volume":"87","author":"JT Said","year":"2022","unstructured":"Said JT, Elman SA, Perez-Chada LM, Mita C, Merola JF, LeBoeuf NR. Treatment of immune checkpoint inhibitor-mediated psoriasis: a systematic review. J Am Acad Dermatol. 2022;87(2):399\u2013400.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1198_CR63","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1158\/2326-6066.CIR-18-0682","volume":"7","author":"D Johnson","year":"2019","unstructured":"Johnson D, Patel AB, Uemura MI, et al. IL17A blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy. Cancer Immunol Res. 2019;7(6):860\u20135.","journal-title":"Cancer Immunol Res"},{"issue":"20","key":"1198_CR64","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1056\/NEJMc1703047","volume":"376","author":"K Esfahani","year":"2017","unstructured":"Esfahani K, Miller WH. Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med. 2017;376(20):1989\u201391.","journal-title":"N Engl J Med"},{"issue":"17","key":"1198_CR65","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714\u201368.","journal-title":"J Clin Oncol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01198-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01198-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01198-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T18:05:37Z","timestamp":1721498737000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01198-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,22]]},"references-count":65,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1198"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01198-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,22]]},"assertion":[{"value":"19 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Vrinda Madan, Laura I. Ortiz- L\u00f3pez, Goranit Sakunchotpanit, Ryan Chen, Krithika Nayudu, and Vinod E. Nambudiri have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study did not require ethical approval from a medical ethics committee as it is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}